WO1997029763A1 - Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique - Google Patents

Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique Download PDF

Info

Publication number
WO1997029763A1
WO1997029763A1 PCT/US1997/001665 US9701665W WO9729763A1 WO 1997029763 A1 WO1997029763 A1 WO 1997029763A1 US 9701665 W US9701665 W US 9701665W WO 9729763 A1 WO9729763 A1 WO 9729763A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
mixtures
growth factor
compositions
composition according
Prior art date
Application number
PCT/US1997/001665
Other languages
English (en)
Inventor
Anne Marie Carella
Paul Joseph Sagel
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to AU18542/97A priority Critical patent/AU1854297A/en
Priority to EP97904185A priority patent/EP0881905A1/fr
Priority to JP9529374A priority patent/JPH11504049A/ja
Publication of WO1997029763A1 publication Critical patent/WO1997029763A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • compositions useful in preventing and/or treating urogenital and intestinal disorders relates to compositions useful in preventing and/or treating urogenital and intestinal disorders
  • Deviations from this delicate floral balance have been etiologically linked to a number of urogenital and/or gastrointestinal tract disorders, such imbalances usually resulting in the proliferation and predominance of pathogenic species Establishing and/or preserving such a delicate floral balance is, therefore, essential to maintaining optimal 0 health
  • lactic acid bacteria e.g., lactobacillus or bifidobacterium
  • growth factors selectively provide lactic acid bacteria with nutrients and an environment essential for continued growth Despite such selectivity, however, alternative nutrient sources remain available for pathogenic bacteria.
  • growth substrates fail to provide direct activity against offending microorganisms. Therefore, notwithstanding such 0 proposals, there still remains a need for improved urogenital and gastrointestinal tract compositions containing lactic acid bacteria growth factors
  • compositions incorporating plants or extracts of the Ericaceae family with Lactobacillus and/or Bifidobacterium provide improved compositions for treating and/or preventing urogenital and gastrointestinal 5 disorders by modifying the interaction of pathogens with cellular tissue
  • Vaccinium e.g. cranberry and blueberry
  • a high molecular weight compound that inhibits the adhesion of common urinary pathogens (e.g., E. coli) to infection sites within the urinary tract.
  • common urinary pathogens e.g., E. coli
  • the compositions of the present invention provide improved environments more conducive to the colonization of lactic acid bacteria.
  • an object of the present invention is to promote a healthy environment for the growth of lactic acid bacteria in the urogenital and gastrointestinal tracts.
  • Another object of the present invention is to provide improved compositions comprising a growth factor for lactic acid bacteria.
  • a further object of the present invention is to provide compositions for dietary supplementation.
  • a still further object of the present invention is to provide topical compositions for vaginal use.
  • An even further object of the present invention is to provide compositions and methods effective in preventing and/or treating urogenital and intestinal disorders.
  • the present invention relates to compositions for the treatment or prevention of urogenital and intestinal disorders, comprising: a.) at least one plant species of the Ericaceae family or its extract; and b.) an effective amount of a growth factor for facilitating the growth of lactic acid bacteria selected from the group consisting of glycogen, rhamnose, gangliosides, salicin, oligosaccharides, galactose, lactulose, methyl- ⁇ -D- mannoside, p-nitrophenoi- ⁇ -D-mannoside, maltose, dextrin, dextran, levan, sialic acid, acetylglucosamine, yeast extracts, peptone, keratin, vegetable, soy, lauric acid, glycerophosphates and mixtures thereof.
  • urogenital and intestinal compositions means a product which in the ordinary course of usage may be retained in the oral cavity, swallowed or applied topically to provide ur
  • urogenital means that system of organs concerned with the production and excretion of urine and reproduction.
  • intestinal means of or relating to the intestines. All percentages and ratios used herein are by weight unless otherwise specified Also, all measurements referred to herein are made at 25°C unless otherwise specified DETAILED DESCRIPTION OF THE INVENTION The essential as well as optional components of the compositions of the present invention are described in the following paragraphs.
  • the Ericaceae (heath) family consisting of about 110 genera and 4,000 species, is by far the most important family of the Ericales order, encompassing a wide variety of fruit producing shrubbery and evergreen plants
  • Genera falling under Ericaceae family include Vaccinium, Arctostaphylos, Gaultheria, and Gaylussacia
  • the Arctostaphylos genus includes such species as the checkerberry and bearberry (Uva ursi).
  • Other edible fruits such as the creeping snowberry or moxie plum fall under the genus Gaultheria Huckleberries are a well known species of the genus Gaylussacia.
  • the Vaccinium genus best known for its fruits, contain some of the most common of berries, including the blueberry (e.g., V. australe), cranberry (e.g., V. macrocarpori) and bilberry (e.g , V. myrtillus).
  • blueberry e.g., V. australe
  • cranberry e.g., V. macrocarpori
  • bilberry e.g , V. myrtillus
  • E. coli adherence results primarily from adhesins on the raised hair like fimbriae (or pili) of the microorganism. These adhesins are designated MS (mannose-sensitive) and MR (mannose-resistant). Like most fruit, Ericacease fruit species contain fructose, an inhibitor of MS adhesins. However, it has been recently suggested that the plants or extracts of Ericaceae species further contain an unidentified, non-dialyzable polymeric compound which inhibits the MR adhesins associated with pyelonephritogenic strains of E. Coli. The unidentified polymeric compound, as studied in Vaccinium species, was found to inhibit both urinary and fecal isolates of E.
  • anti-adhesive activity means an amount effective to inhibit the adhesion of pathogenic microorganisms to the epithelial and/or mucosal lining of the urogenital and/or intestinal tract.
  • Plants or extracts useful in the compositions of the present invention come from a wide range of genera within the Ericaceae family including, but not limited to, Vaccinium, Arctostaphylos, Gaultheria, and Gaylussacia.
  • Preferred species include, V. australe, V. corymbosum, V. occidentale, V. ovatum, V. myrtillus, V. parvifolium, V. uliginosum, V. macrocarp ⁇ n, V. oxycoccus, V.
  • erythrocarpum V. vitis-idaea. V. australe, V. macrocarpon.
  • Vaccinium species most preferred for use in the present invention include V. australe, V. macrocarpon, and V. myrtillus. Mixtures of Ericaceae plants and/or extracts may also be used.
  • the plants or extracts of the present invention are preferably concentrated, having a ratio of at least about 4 pounds of plant concentrate or extracts per pound of concentrate, more preferably from about 4 pounds of plant concentrates or extracts per pound of concentrate to about 50 pounds of plant concentrate or extracts per pound of concentrate.
  • the Ericaceae extracts are preferably present at a level of at least lOmg, more preferably from about lOOmg to about 18g, most preferably from about 250mg to about 4g per unit dose.
  • the amount of extract contained in each dose of product can be adjusted for the dosage form. For example, the amount of extract in powdered form used in a drink mix can range up to 18g per dose while the amount used in swallowable capsules might range to about 4g.
  • Preferred levels of the Ericaceae plants or extracts provide urinary and/or intestinal tract fluid concentrations of the above mentioned unidentified, non-dialyzable polymeric compound of from about 12 to about 25 micrograms per milliliter. Also, the plants or extracts of the present invention preferably retain greater than 2.5% of their total acid content and greater than about 0.1% of their benzoic acid content. The level selected to provide the desired level of anti-adhesin activity and can be modified as desired. Cranberries and cranberry extracts are useful in the treatment and/or prophylaxis of urinary tract infections and are also useful as vaginal deodorants. Growth Factor for Lactic acid Bacteria
  • compositions of the present invention also incorporate a growth factor for lactic acid bacteria
  • a growth factor for facilitating the growth of lactic acid bacteria means a nutrient source or media which supplies a necessary source of food and/or energy for facilitating the growth of lactic acid producing bacteria
  • the growth factor is preferably selective for establishing and maintaining the growth of lactic acid bacteria, preferably Lactobacillus and/or Bifidobacterium species, without facilitating extreme growth of pathogenic bacteria
  • the various nutritional requirements essential for bacterial and/or colony growth are normally met when the growth factor contains fermentable carbohydrate, peptone, meat or yeast extract Supplementations with tomato juice, manganese, acetate and oleic acid esters, especially Tween 80, are stimulatory or even essential for most species and are, therefore, included in most MRS medium Lactic acid bacteria adapted to very particular substrates may require special growth factors.
  • Growth factors suitable for use in the present invention are selected from the group consisting of glycogen; D-mannose; mannitol; escuiine; lactose; saccharose; trehalose; D- raffinose; gentibiose; giuconate; rha nose; gangliosides; salicin, oligosaccharides; galactose, lactulose; methyl- ⁇ -D-mannoside; p-nitrophenol- ⁇ -D-mannoside, maltose, dextrin, maltodextrin; dextran; levan, sialic acid; acetylglucosamine; yeast extracts, proteinacious materials such as, peptone, keratin, vegetable, soy and unsaturated fatty acids such as lauric acid and teichoic acids such as lipoteichoic acid and esters such as glycerophosphates or ⁇ -glycerophosphates.
  • Fiber or fermentable substrates such as psyllium may be used in the present compositions as may gums such as guar gum and xanthan gum.
  • gums such as guar gum and xanthan gum.
  • vaginally monosaccharides such as fructose and glucose as well as whey proteins may also be inco ⁇ orated.
  • the growth factor is preferably selected from the group consisting of rhamnose, oligosaccharides and glucogen
  • the growth factor of the present invention is an oligosaccharide such as, but not limited to, galactooligosaccharides, soybean oligosaccharides and fructooligosaccharides.
  • oligosaccharides In addition to being a carbohydrate source, oligosaccharides also possess bioadhesive properties which help fix the location of these growth factors for easier access by lactic acid bacteria. Most preferred for use herein are fructooligosaccharides.
  • Lactic acid bacteria such as Lactobacillus and Bifidobacterium, partially utilize fructooligosaccharides as an energy source by converting it, via fermentation, to lactic acid or a mixture of lactic acid, acetic acid, and CO2
  • the lactic acid and other fatty acids produced by this carbohydrate fermentation contribute to the maintenance of low pH which is an important control mechanism for preventing colonization of pathogens.
  • Inulin is prepared by hot water extraction of chicory roots and is composed of molecules of the GFn type, n ranging as high as 60 with an average degree of polymerization of 10.
  • Fructooligosaccharides suitable for use herein may or may not have non-fructosyl units in place of fructosyl end units.
  • Non-fructosyl units may include, but are not limited to, polyalcohols such as xylitol, mannitol, and sorbitol.
  • Fructooligosaccharides most preferred for use in the present compositions are inulin or oligofructose. Mixtures of these nutrients may also be used.
  • Growth factors are preferably inco ⁇ orated into the compositions of the present invention at from about 5% to about 75%, more preferably from about 20% to about 70%, and most preferably from about 30% to about 65% per unit dose.
  • OPTIONAL COMPONENTS are preferably inco ⁇ orated into the compositions of the present invention at from about 5% to about 75%, more preferably from about 20% to about 70%, and most preferably from about 30% to about 65% per unit dose.
  • An optional component of the present invention is a viable colony of Lactobacillus or Bifidobacterium.
  • Bacteria of the Lactobacillus genus are characterized as rod-shaped, gram-positive and non-spore-forming bacteria.
  • Lactobacillus inhabit the urogenital and gastrointestinal tracts of animals and humans and are important members of lactic acid producing group of bacteria.
  • Various species of Lactobacillus are used commercially in the production of sour milks, cheeses and yogurt. Lactobacilli also share an important role in the manufacture of fermented vegetables (e.g., pickles and sauerkraut), beverages (e.g., beer, wine and juices), sourdough breads, and some sausages.
  • Lactobacillus species suitable for use in the present invention are those which 1.) readily adhere to the epithelial cells of either the urogenital or gastrointestinal tracts of mammals; 2.) produce hydrogen peroxide; 3.) promote low pH; and produce bacteriocins.
  • bacteriocins means proteinaceious, bacteriocidal substances synthesized by bacteria, which usually have a narrow spectrum of activity, inhibiting strains of the same or closely related species. Bacteriocins appear to be capable of displacing or suppressing the growth of other bacteria, and as such may provide an advantage to microorganisms in fermenting the female genital tract ecosystem.
  • Preferred species of Lactobacillus include L. acidophilus, L. johnsonii, L.
  • Lactobacillus species of the present invention are hydrogen peroxide producing such as L. acidophilus, L. catenaforme, L.
  • L. crispatus, L. delbrueckii, L. jensenii, L rogosae. L. fermentum, L. gasseri and L. plantarum are also preferred for use herein in view of their adhesive properties.
  • Bifidobacterium species are non-acid-fast, nonmotile gram negative rods. Lactic and acetic acid producing Bifidobacteria are also considered important regulators of the urogenital and intestinal flora of mammals.
  • Species suitable for use in the present compositions include, but are not limited to, B. longum, B. breve, Lactobacillus Bifidus and Lactobacillus bifidus subsp pennsylvanicus.
  • Preferred for use in the present compositions is B. Bifidum, most preferred B. Bifidum subsp. Pennsylvanicus.
  • Lactobacillus and/or Bifidobacterium species may also be used. Any of the above species may be obtained either commercially or through laboratory cultures.
  • the Lactobacillus and/or Bifidobacterium species are present at levels of at least about 10 ⁇ cells per unit dose, preferably at levels of from about 10 ⁇ to about 10 ⁇ 2 ce n s per unit dose and most preferably at levels of from about 10 ⁇ to about 10 ⁇ cells per unit dose.
  • unit dose means physically discrete units suitable as unitary dosages for administration to mammals, each such unit containing a predetermined quantity of an active ingredient calculated to produce the desired therapeutic effect in association with pharmaceutically acceptable carriers.
  • the level is selected to provide the desired level of urogenital and gastrointestinal activity and can be modified as desired.
  • Lactobacillus may loose 4-6 fold of its viability at room temperature and during manufacturing, so depending on the manufacturing conditions, an excess of Lactobacillus is added to maintain an adequate number of viable organisms per final unit dose form.
  • a patient can be administered the equivalent of these concentrations of organisms where the values are expressed by some other measurement such as, for example, total protein concentration.
  • compositions of the present invention may also contain a buffering agent.
  • buffering to an acidic pH to enhance flavor may be done.
  • buffering agents suitable for use in the compositions of the present invention are those capable of maintaining a urogenital pH of 3.0 to 5.5. Any mild pharmaceutically acceptable acid, other than those found in the Ericaceae species disclosed herein, can be used.
  • Suitable acids include boric acid, or organic acids such as quinnic acid, proprionic acid, malic acid, pyruvic acid, hippuric acid, tartaric acid, sorbic acid, benzoic acid, lactic acid, ascorbic acid, citric acid, or acetic acid, in combination with their respective sodium or other pharmaceutically acceptable salt (to the extent necessary to achieve the desired pH).
  • the compositions of the present invention are preferably buffered to a pH range of from about 3.5 to about 5.0, preferably from about 3.7 to about 4.7, and preferably using lactic acid with sodium lactate or a combination lactic acid/sodium lactate and benzoic acid or lactic acid/sodium lactate and proprionic acid.
  • Additional therapeutic and/or medicinal plants or extracts may also be inco ⁇ orated into the compositions of the present invention.
  • Such plants or extracts include echinacea, allium, bucha, juniper ginseng, allicin, chloretla, aigin and the like. Mixtures of these additional plants or extracts may also be used.
  • Nutritional Additives include echinacea, allium, bucha, juniper ginseng, allicin, chloretla, aigin and the like. Mixtures of these additional plants or extracts may also be used.
  • Nutritional additives may also be inco ⁇ orated into the compositions of the present invention.
  • Such additives include, but are not limited to, proteins and carbohydrates other than those mentioned herein as growth factors, vitamins such as nicotinic acid, pantothenic acid, and riboflavin; minerals such as manganese; phytochemicals; amino acids such as serine, glutamine, methionine, glycine, cysteine, leucine, isoleucine, threonine, valine.
  • compositions of the present invention may also be used in combination with pharmaceutical actives.
  • the pharmaceutical active is preferably selected from at least one of an analgesic agent and/or a gastrointestinal agent.
  • analgesics preferred for use in the present invention include acetaminophen, acetyl salicylic acid, indomethacin and optically active isomers or racemates of ibuprofen, naproxen, flurbiprofen, ca ⁇ rofen, tiaprofenic acid, cicloprofen, ketoprofen, ketorolac, etodolac, indomethacin, sulindac, fenoprofen, diclofenac, piroxicam, benzydomine, nabumetone, their pharmaceutically acceptable salts and mixtures thereof.
  • gastrointestinal agents preferred for use in the present invention include anticholinergics including atropine, clidinium and dicyclomine; antacids including aluminum hydroxide, bismuth subsalicylate, bismuth subcitrate, simethicone, calcium carbonate and magaldrate; H2 ⁇ receptor antagonists including cimetidine, famotidine, nizatidine and ranitidine; laxatives including: docusate, phenolphthalein and casanthrol; gastroprotectants including sucralfate and sucralfate humid gel; gastrokinetic agents including metoclopramide and cisapride; proton pump inhibitors including omeprazole and antidiarrheals including: diphenoxylate, kaolin pectin, attapulgite and loperamide.
  • anticholinergics including atropine, clidinium and dicyclomine
  • antacids including aluminum hydroxide, bismuth subsalicylate, bismuth subcitrate
  • compositions of the present invention are many and varied and depend largely upon the end use of the compositions. These carriers include orally acceptable as well as topical compositions. They may be completely inert or contain or may be other active ingredients, yet the carriers must be compatible with the herein disclosed compositions.
  • compatible means that the carrier components are capable of being commingled with the components of the present invention, and with each other, in a manner such that there is no interaction which would substantially reduce the activity of the compositions under ordinary use situations.
  • Carrier materials must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human being treated.
  • the compositions of the present invention comprise from about 0.01% to about 99.99% of one or more carrier materials.
  • Carriers suitable for topical administration of the present compositions include suppositories, vaginal tablets or capsules, ovules, creams, solutions for lavages, emulsions, foams, soaps, gels, liniments, oils and ointments.
  • Creams and gels, other base formulations may be used in topical administration of the present compositions to, for example, the genital region and are prepared according to conventional methods for semi-solid compositions using excipients like vaseline, paraffin, vaseline oil, vegetable oils, animal oils, solid and liquid synthetic glycerides, waxes, lanolin, lanolin alcohols, sorbitan esters, fatty alcohols, liquid/solid polyethylene glycols, propylene glycols, polyethylene, starch, acrylamides, methacrylamides, derivatives of cellulose and carboxyvinylpolymers.
  • excipients like vaseline, paraffin, vaseline oil, vegetable oils, animal oils, solid and liquid synthetic glycerides, waxes, lanolin, lanolin alcohols, sorbitan esters, fatty alcohols, liquid/solid polyethylene glycols, propylene glycols, polyethylene, starch, acrylamides, methacrylamides, derivatives of cellulose and carboxyvinyl
  • Ovules, suppositories, vaginal capsules or tablets and effervescent tablets may also be useful in topical application of the prevention.
  • Ovules are similar to suppositories, ovoidal shaped and the excipients mainly used are semi-synthetic glycerides and polyethylene glycols and optionally also emulsifiers and surfactants.
  • the vaginal capsules are gelatinous envelopes or sachets within which is subdivided the suspension which is generally anhydrous and contains liquid paraffin, vaseline, vegetable oils and semi-synthetic oils and thickening agents.
  • the tablets, shaped suitably for vaginal use contain as main excipients lactose, starch, polyvinylpyrrolidone, cellulose derivatives, magnesium stearate, glycol.
  • the effervescent tablets contain chemical components (i.e. sodium bicarbonate with citric acid or tartaric acid), which are necessary to develop carbon dioxide in order to produce effervescence.
  • compositions of the present invention may also be inco ⁇ orated into and topically applied by woven or nonwoven fabric materials such as tissues, wipes, feminine napkins, panty liners, tampons, diapers, incontinent care products and the like.
  • Preferred for use herein are nonwoven fabrics.
  • Nonwoven fabrics suitable for inco ⁇ orating the present compositions are described in U.S. Patent 4,891,227 to Tha an et al., herein inco ⁇ orated by reference.
  • Oral dosage forms are also useful as carriers for the present invention. These dosage forms contain compatible solid or liquid filler diluents or encapsulating substances which are suitable for oral administration to a human or lower animal.
  • Liquid dosage forms for oral administration may comprise dissolving or suspending the compositions of the present invention in a potable liquid, such as sterile or distilled water.
  • liquid or dry oral administration forms can comprise an enterically coated capsule containing the dosage forms.
  • Suitable forms include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water, sugars, polysaccharides, silicate gels, gelatin, or an alcohol. These inert diluents do not actively participate in the therapeutic effect of the present invention.
  • compositions can also contain wetting agents, emulsifying agents, suspending agents, as well as additional therapeutic actives
  • wetting agents emulsifying agents
  • suspending agents emulsifying agents
  • additional therapeutic actives emulsifying agents
  • Tablets can be compressed, molded, triturated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, and flow-inducing agents.
  • Tablets may be enteric-, film- or sugar-coated Protein-like coating components may also be included. Useful for improvement of gastrointestinal disorders, such components may contain branched amino acid-modified proteins.
  • Whey powders for example, are treated with papain in the presence of the amino acids ethyl L-leucine (16.1 parts), ethyl L- isoleucine (7.4 parts), ethyl L-valine (10.2 parts), cysteine hydrochloride (1.5 parts), and sodium carbonate (26 parts) in water at 40°C for 20 minutes to manufacture coated powders containing 10% free amino acids and 43% branched amino acids.
  • the branched amino acid-modified powders can be mixed with fats, dextrins, salts, vitamins, and the like to make tablets.
  • a tablet coating materials are zeolites and clays to make tablets more palatable. Zeolites have found use as bacterial feed coatings for domestic animals. For example, in the domestic animal business, timeline fumarate is dissolved in methanol, supported on mordenite-type zeolite or starch, dried and further premixed with the supports to produce sustained-release, coated granules. Still other examples of tablet coatings include complex carbohydrate and inclusion complexes.
  • soft or hard gelatin capsules are also useful.
  • the gelatin shell is essentially transparent so as to enhance the aesthetic qualities of the capsule.
  • Soft and hard gelatin shells generally comprise gelatin, a plasticizer and water.
  • the starting gelatin material generally used in the manufacture of these capsules is obtained by the partial hydrolysis of collagenous material.
  • Gelatin suitable for capsule manufacture is commercially available from the Sigma Chemical Company, St. Louis, Mo.
  • One or more plasticizers is inco ⁇ orated to produce a gelatin shell.
  • Useful plasticizers of the present invention include glycerin, sorbitan, sorbitol, or similar low molecular weight polyols, and mixtures thereof.
  • compositions of the present invention may be achieved by inco ⁇ orating the compositions of the present invention into freeze-dried or lyophilized tablets. Freeze-drying or lyophilization facilitates disintegration of the composition by forming the dried composition into an open matrix network. In most cases, this results in rapid permeation by the aqueous media, promoting timely delivery of the product.
  • Suitable methods of freeze drying are well known in the art and commonly employed. Any suitable conventional method of freeze-drying may be utilized. A preferable method of freezing and drying is to fast freeze the composition and then dry the composition to a final moisture content of about 2% to about 5%. Suitable methods of freeze-drying and production are taught by U.S. Patent 4.642.903. February 17, 1987, to Davies, U.S.
  • the compositions of the present invention may be vacuum dried.
  • Vacuum drying involves at least the partial drying of compositions at temperatures above compositions' collapse temperature. Freeze drying, on the other hand, involves the drying of compositions at temperatures below the composition's collapse temperature. Any suitable method of vacuum drying may be used. Suitable vacuum drying processes are described in U.S. Patent 5.298.261. to Pebley et al., issued March 29, 1994, herein inco ⁇ orated by reference.
  • One other form of tableting technology that may be applicable to the present invention is a liquid/liquid extract developed by Janssen Pharmaceutica Inc. and is identified by the trade name QuicksolvTM. This technology is fully described in U.S. Patent 5.215.756. herein inco ⁇ orated by reference.
  • ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants, perfuming agents, buffering agents and the like to provide a palatable and pleasant looking final product, antioxidants, for example, butylated hydroxy anisole or butylated hydroxy toluene, and preservatives, for example, methyl or propyl paraben, potassium sorbate, or sodium benzoate, to prolong and enhance shelf life.
  • a preferred optional component is also caffeine.
  • Example I A tablet form of the present invention is made by combining the following components using conventional mixing and tableting technology. Ingredient % Weight
  • the cranberry extract and fructooligosaccharide are granulated with 5% ethylcellulose in ethanol.
  • the granulation is then passed through a 12 mesh screen and dried at 120°F.
  • To the dried granulation is added stearic acid.
  • the granulation mixture is passed through a 20 mesh screen.
  • To the sieved granulation is added the starch and talc and mixing until uniform.
  • the resultant granulation mixture is then compressed using conventional tableting processes.
  • Example II A capsule form of the present invention is made by combining the following components using conventional mixing technology.
  • Example III A topical gel form of the present invention is made by combining the following components using conventional mixing technology.
  • compositions may also contain a growth factor such as glycogen, rhamnose, oligosaccharides, lactulose, methyl- ⁇ -D-mannoside, p- nitrophenol- ⁇ -D-mannoside, maltose, dextrin, levan, acetylglucosamine, amino acids, proteinacious materials such as, peptone, keratin, vegetable, soy, glycerophosphates and mixtures thereof.
  • a growth factor such as glycogen, rhamnose, oligosaccharides, lactulose, methyl- ⁇ -D-mannoside, p- nitrophenol- ⁇ -D-mannoside, maltose, dextrin, levan, acetylglucosamine, amino acids, proteinacious materials such as, peptone, keratin, vegetable, soy, glycerophosphates and mixtures thereof.
  • suitable ingredients, diluents and dosage forms or readily ascertain such using routine experimentation

Abstract

Compositions utiles pour prévenir et/ou traiter des troubles urogénitaux et intestinaux, qui contiennent une quantité efficace d'au moins une espèce végétale de la famille des Ericaceae ou de son extrait et une quantité efficace d'un facteur de croissance qui stimule la croissance de bactéries de l'acide lactique. Ledit facteur de croissance est choisi parmi glycogène, rhmanose, gangliosides, salicine, oligosaccharides, galactose, lactulose, méthyl-α-D-mannoside, ς-nitrophénol-α-D-mannoside, maltose, dextrine, dextrane, lévane, acide sialique, acétylglucosamine, extraits de levures, peptone, kératine, légumes, soja, acide laurique, glycérophosphates et des mélanges desdites substances.
PCT/US1997/001665 1996-02-14 1997-02-06 Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique WO1997029763A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU18542/97A AU1854297A (en) 1996-02-14 1997-02-06 Urogenital and intestinal disorder compositions comprising substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
EP97904185A EP0881905A1 (fr) 1996-02-14 1997-02-06 Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique
JP9529374A JPH11504049A (ja) 1996-02-14 1997-02-06 ツツジ科の植物種より由来する物質および乳酸バクテリア成長因子を含む泌尿生殖器および腸の疾患用の組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60148296A 1996-02-14 1996-02-14
US08/601,482 1996-02-14
US63009696A 1996-04-09 1996-04-09
US08/630,096 1996-04-09

Publications (1)

Publication Number Publication Date
WO1997029763A1 true WO1997029763A1 (fr) 1997-08-21

Family

ID=27083871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/001665 WO1997029763A1 (fr) 1996-02-14 1997-02-06 Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique

Country Status (6)

Country Link
EP (1) EP0881905A1 (fr)
JP (1) JPH11504049A (fr)
CN (1) CN1211189A (fr)
AU (1) AU1854297A (fr)
CA (1) CA2246371A1 (fr)
WO (1) WO1997029763A1 (fr)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1014969A1 (fr) * 1997-09-09 2000-07-05 Rutgers, The State University of New Jersey Extrait de proanthocyanidine d'origine vegetale empechant efficacement une adherence de bacteries a fimbriae de type p a des surfaces
WO2001017364A1 (fr) * 1999-09-06 2001-03-15 Effem Foods Pty Ltd Produit alimentaire et procede pour le fabriquer
EP1090648A2 (fr) * 1999-10-07 2001-04-11 Symbio Herborn Group GmbH & Co. Tampon à utilisation dans les cavités corporelles
EP1133306A1 (fr) * 1998-11-19 2001-09-19 Malireddy S. Reddy Medicaments a base de plantes et produits pharmaceutiques a action accentuee par des probiotiques
AU744623B2 (en) * 1998-05-19 2002-02-28 Pennsylvania State University, The Broad spectrum microbicidal and spermicidal compositions, devices, and methods
WO2002100402A1 (fr) * 2001-06-11 2002-12-19 The Procter & Gamble Company Compositions a base de nitrofurantoine et d'uva ursi
KR20030066902A (ko) * 2002-02-06 2003-08-14 주식회사 코리즈 레반을 포함하는 장내유산균 생육촉진 조성물
US6632796B1 (en) * 1997-11-24 2003-10-14 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
GB2396811A (en) * 2002-12-23 2004-07-07 Forum Bioscience Holdings Ltd Compositions comprising plant extract and sugar for use in inhibiting bacterial proliferation
WO2004067013A1 (fr) * 2003-01-24 2004-08-12 Flora Technology Inc. Compositions et procedes pour restaurer la flore bacterienne
FR2856304A1 (fr) * 2003-06-20 2004-12-24 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
WO2005016300A2 (fr) * 2003-07-22 2005-02-24 Kimberly-Clark Worldwide, Inc. Lingette et procedes d'amelioration de la sante dermatologique
WO2005110504A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits de soins personnels et methode pour inhiber l'adherence de flore bacterienne sur la peau
EP1600060A1 (fr) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Composition orale et/ou topique contenant des prébiotiques et acides gras
EP1600062A1 (fr) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Composition orale et/ou topique contenant des prébiotiques et des stéroles
EP1614357A1 (fr) * 2004-07-10 2006-01-11 Cognis IP Management GmbH complément alimentaire contenant des prébiotiques et des acides gras
FR2874825A1 (fr) * 2004-09-08 2006-03-10 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
EP1879469A2 (fr) * 2005-05-11 2008-01-23 Hill's Pet Nutrition Inc. Procedes pour augmenter l'appetibilite de compositions destinees a la consommation animale
EP1911454A1 (fr) * 2005-04-27 2008-04-16 HK Phlora Health Sci. & Tech. Limited Composition et procédé de régulation et de maintien de la flore bactérienne vaginale et de l'acidité normale dans le vagin
GB2453671A (en) * 2007-10-11 2009-04-15 Fayrefield Foods Ltd Preparation for use in the treatment of Clostridium difficile and Salmonella
US7528113B2 (en) 1999-11-26 2009-05-05 Adenovir Pharma Ab Method and composition for the treatment of adenoviral ocular infections
US20100063000A1 (en) * 2006-12-28 2010-03-11 Takashi Furuyashiki Food containing glycogen and use thereof
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
US7785640B2 (en) 2004-01-16 2010-08-31 Amerilab Technologies, Inc. Effervescent composition including cranberry extract
US7794746B2 (en) 2002-12-12 2010-09-14 Nestec S.A. Prebiotic compositions
US8309073B2 (en) 2001-01-25 2012-11-13 Valio Ltd. Combination of probiotics
WO2013167707A1 (fr) * 2012-05-08 2013-11-14 Progressare Medinvest B.V. Composition pour le traitement ou la prévention d'infections des voies urinaires et forme galénique
US20140294790A1 (en) * 2008-01-11 2014-10-02 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
WO2017058174A1 (fr) * 2015-09-29 2017-04-06 Kimberly-Clark Worldwide, Inc. Composition pour le maintien de la dominance de lactobacillus
RU2637650C2 (ru) * 2016-03-29 2017-12-05 Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" Композиция для профилактики заболеваний мочевыводящих путей
EP3320897A1 (fr) * 2016-11-14 2018-05-16 Dompè Primary S.r.l Préparation de granules de cranberry enrobés à teneur stable en proanthocyanidines
WO2018100533A1 (fr) 2016-11-30 2018-06-07 Probioswiss Ag Formulation de dispositif médical urogénital à base de compositions biochimiques appropriées pour la stabilisation de l'acidité et de l'état redox des sécrétions vaginales
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CN113662175A (zh) * 2021-08-16 2021-11-19 广州市沐家健康产业有限公司 一种植物基酵素液排毒养颜组合物及其制备方法
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243273A1 (fr) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques
EP1319410A1 (fr) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Utilisation de microorganismes pour l'administration ciblée de substances dans des parties spécifiques de l'intestin
AU2009263566B2 (en) * 2008-06-24 2012-08-30 Morinaga Milk Industry Co., Ltd. Diluting solution for suspension for use in the measurement of number of living microbial cells contained in sample, and method for measurement of number of living microbial cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427014A1 (de) * 1984-07-21 1986-01-23 Moser, Hanspeter H., Dr.med., 3012 Langenhagen Praeparat zur prophylaxe und therapie unkomplizierter harnwegsinfekte
SU1329745A1 (ru) * 1984-10-10 1987-08-15 Ленинградский технологический институт холодильной промышленности Способ производства напитка из молочной сыворотки
JPH0416163A (ja) * 1990-05-02 1992-01-21 Nippon Synthetic Chem Ind Co Ltd:The 整腸用組成物
SU1708342A1 (ru) * 1989-10-04 1992-01-30 Научно-производственное объединение "Аэрозоль" Крем дл ухода за кожей после брить
WO1993000067A1 (fr) * 1991-06-27 1993-01-07 Bioeurope Compositions cosmetiques contenant des oligosaccharides
WO1995026197A1 (fr) * 1994-03-25 1995-10-05 Jlb, Inc. Composition inhibant l'adhesion
JPH0919276A (ja) * 1995-07-06 1997-01-21 Roozu Mei:Kk 健康美容飲料

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427014A1 (de) * 1984-07-21 1986-01-23 Moser, Hanspeter H., Dr.med., 3012 Langenhagen Praeparat zur prophylaxe und therapie unkomplizierter harnwegsinfekte
SU1329745A1 (ru) * 1984-10-10 1987-08-15 Ленинградский технологический институт холодильной промышленности Способ производства напитка из молочной сыворотки
SU1708342A1 (ru) * 1989-10-04 1992-01-30 Научно-производственное объединение "Аэрозоль" Крем дл ухода за кожей после брить
JPH0416163A (ja) * 1990-05-02 1992-01-21 Nippon Synthetic Chem Ind Co Ltd:The 整腸用組成物
WO1993000067A1 (fr) * 1991-06-27 1993-01-07 Bioeurope Compositions cosmetiques contenant des oligosaccharides
WO1995026197A1 (fr) * 1994-03-25 1995-10-05 Jlb, Inc. Composition inhibant l'adhesion
JPH0919276A (ja) * 1995-07-06 1997-01-21 Roozu Mei:Kk 健康美容飲料

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8812, Derwent World Patents Index; AN 88-082499, XP002030870 *
DATABASE WPI Week 9209, Derwent World Patents Index; AN 92-070065 *
DATABASE WPI Week 9319, Derwent World Patents Index; AN 93-157317, XP002030871 *
DATABASE WPI Week 9713, Derwent World Patents Index; AN 97-139596, XP002030869 *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 168 (C - 0932) 22 April 1992 (1992-04-22) *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1014969A4 (fr) * 1997-09-09 2004-09-15 Univ Rutgers Extrait de proanthocyanidine d'origine vegetale empechant efficacement une adherence de bacteries a fimbriae de type p a des surfaces
EP1014969A1 (fr) * 1997-09-09 2000-07-05 Rutgers, The State University of New Jersey Extrait de proanthocyanidine d'origine vegetale empechant efficacement une adherence de bacteries a fimbriae de type p a des surfaces
US6632796B1 (en) * 1997-11-24 2003-10-14 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
AU744623B2 (en) * 1998-05-19 2002-02-28 Pennsylvania State University, The Broad spectrum microbicidal and spermicidal compositions, devices, and methods
EP1133306A1 (fr) * 1998-11-19 2001-09-19 Malireddy S. Reddy Medicaments a base de plantes et produits pharmaceutiques a action accentuee par des probiotiques
EP1133306A4 (fr) * 1998-11-19 2006-05-03 Malireddy S Reddy Medicaments a base de plantes et produits pharmaceutiques a action accentuee par des probiotiques
WO2001017364A1 (fr) * 1999-09-06 2001-03-15 Effem Foods Pty Ltd Produit alimentaire et procede pour le fabriquer
US7258879B1 (en) 1999-09-06 2007-08-21 Mars, Inc. Food product and process for manufacturing same
EP1090648A2 (fr) * 1999-10-07 2001-04-11 Symbio Herborn Group GmbH & Co. Tampon à utilisation dans les cavités corporelles
EP1090648A3 (fr) * 1999-10-07 2003-01-29 Symbio Herborn Group GmbH & Co. Tampon à utilisation dans les cavités corporelles
US7528113B2 (en) 1999-11-26 2009-05-05 Adenovir Pharma Ab Method and composition for the treatment of adenoviral ocular infections
US8309073B2 (en) 2001-01-25 2012-11-13 Valio Ltd. Combination of probiotics
WO2002100402A1 (fr) * 2001-06-11 2002-12-19 The Procter & Gamble Company Compositions a base de nitrofurantoine et d'uva ursi
KR20030066902A (ko) * 2002-02-06 2003-08-14 주식회사 코리즈 레반을 포함하는 장내유산균 생육촉진 조성물
US7794746B2 (en) 2002-12-12 2010-09-14 Nestec S.A. Prebiotic compositions
US8241658B2 (en) 2002-12-12 2012-08-14 Nestec S.A. Prebiotic compositions
WO2004056380A3 (fr) * 2002-12-23 2004-09-16 Forum Bioscience Holdings Ltd Composition comprenant un extrait d'une plante et un sucre et pouvant etre utilisee pour inhiber une proliferation bacterienne
WO2004056380A2 (fr) * 2002-12-23 2004-07-08 Forum Bioscience Holdings Limited Composition comprenant un extrait d'une plante et un sucre et pouvant etre utilisee pour inhiber une proliferation bacterienne
GB2396811A (en) * 2002-12-23 2004-07-07 Forum Bioscience Holdings Ltd Compositions comprising plant extract and sugar for use in inhibiting bacterial proliferation
WO2004067013A1 (fr) * 2003-01-24 2004-08-12 Flora Technology Inc. Compositions et procedes pour restaurer la flore bacterienne
FR2856304A1 (fr) * 2003-06-20 2004-12-24 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
WO2004112775A1 (fr) * 2003-06-20 2004-12-29 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
KR101159857B1 (ko) * 2003-07-22 2012-06-25 킴벌리-클라크 월드와이드, 인크. 피부 건강을 향상시키기 위한 와이프 및 방법
US10022308B2 (en) 2003-07-22 2018-07-17 Kimberly-Clark Worldwide, Inc. Wipe and methods for improving skin health
WO2005016300A3 (fr) * 2003-07-22 2005-04-21 Kimberly Clark Co Lingette et procedes d'amelioration de la sante dermatologique
WO2005016300A2 (fr) * 2003-07-22 2005-02-24 Kimberly-Clark Worldwide, Inc. Lingette et procedes d'amelioration de la sante dermatologique
US8168240B2 (en) 2004-01-16 2012-05-01 Amerilab Technologies, Inc. Effervescent composition including cranberry extract
US7785640B2 (en) 2004-01-16 2010-08-31 Amerilab Technologies, Inc. Effervescent composition including cranberry extract
GB2430157B (en) * 2004-04-30 2009-02-11 Kimberly Clark Co Personal care products and methods for inhibiting the adherence of flora to skin
US8110215B2 (en) 2004-04-30 2012-02-07 Kimberly-Clark Worldwide, Inc. Personal care products and methods for inhibiting the adherence of flora to skin
WO2005110504A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits de soins personnels et methode pour inhiber l'adherence de flore bacterienne sur la peau
GB2430157A (en) * 2004-04-30 2007-03-21 Kimberly Clark Co Personal care products and methods for inhibiting the adherence of flora to skin
US8329672B2 (en) 2004-05-25 2012-12-11 Cognis Ip Management Gmbh Oral and/or topical compositions comprising prebiotics and fatty acid
WO2005115171A1 (fr) * 2004-05-25 2005-12-08 Cognis Ip Management Gmbh Compositions orales et/ou topiques renfermant des prebiotiques et des sterols
EP1600060A1 (fr) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Composition orale et/ou topique contenant des prébiotiques et acides gras
EP1600062A1 (fr) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Composition orale et/ou topique contenant des prébiotiques et des stéroles
WO2005115172A1 (fr) * 2004-05-25 2005-12-08 Cognis Ip Management Gmbh Preparations orales et/ou topiques comprenant des prebiotiques et des acides gras
EP1614357A1 (fr) * 2004-07-10 2006-01-11 Cognis IP Management GmbH complément alimentaire contenant des prébiotiques et des acides gras
WO2006005464A3 (fr) * 2004-07-10 2006-05-04 Cognis Ip Man Gmbh Complements alimentaires
WO2006005464A2 (fr) * 2004-07-10 2006-01-19 Cognis Ip Management Gmbh Complements alimentaires
FR2874825A1 (fr) * 2004-09-08 2006-03-10 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
WO2006030100A1 (fr) * 2004-09-08 2006-03-23 Genibio Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US8586549B2 (en) 2005-04-27 2013-11-19 Shenzhen Phlora Biotechnology Limited Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity
EP1911454A4 (fr) * 2005-04-27 2009-07-29 Hk Phlora Health Sci & Tech Lt Composition et procédé de régulation et de maintien de la flore bactérienne vaginale et de l'acidité normale dans le vagin
EP1911454A1 (fr) * 2005-04-27 2008-04-16 HK Phlora Health Sci. & Tech. Limited Composition et procédé de régulation et de maintien de la flore bactérienne vaginale et de l'acidité normale dans le vagin
EP1879469A4 (fr) * 2005-05-11 2009-12-16 Hills Pet Nutrition Inc Procedes pour augmenter l'appetibilite de compositions destinees a la consommation animale
EP2401924A1 (fr) * 2005-05-11 2012-01-04 Hill's Pet Nutrition, Inc. Procédés pour augmenter l'appétibilité de compositions destinées à la consommation animale
EP1879469A2 (fr) * 2005-05-11 2008-01-23 Hill's Pet Nutrition Inc. Procedes pour augmenter l'appetibilite de compositions destinees a la consommation animale
US20100063000A1 (en) * 2006-12-28 2010-03-11 Takashi Furuyashiki Food containing glycogen and use thereof
US8461130B2 (en) * 2006-12-28 2013-06-11 Ezaki Glico Co., Ltd. Food containing glycogen and use thereof
GB2453671A (en) * 2007-10-11 2009-04-15 Fayrefield Foods Ltd Preparation for use in the treatment of Clostridium difficile and Salmonella
GB2453671B (en) * 2007-10-11 2009-09-16 Fayrefield Foods Ltd Preparation for use in the treatment of Clostridium difficile and Salmonella
US20140294790A1 (en) * 2008-01-11 2014-10-02 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
US11446340B2 (en) 2011-05-09 2022-09-20 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US11110135B2 (en) 2011-05-09 2021-09-07 Probiotical S.P.A. Bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
WO2013167707A1 (fr) * 2012-05-08 2013-11-14 Progressare Medinvest B.V. Composition pour le traitement ou la prévention d'infections des voies urinaires et forme galénique
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
RU2723015C2 (ru) * 2015-09-29 2020-06-08 Кимберли-Кларк Ворлдвайд, Инк. Композиция для поддержания доминирования лактобактерий
WO2017058174A1 (fr) * 2015-09-29 2017-04-06 Kimberly-Clark Worldwide, Inc. Composition pour le maintien de la dominance de lactobacillus
RU2637650C2 (ru) * 2016-03-29 2017-12-05 Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" Композиция для профилактики заболеваний мочевыводящих путей
WO2018087351A1 (fr) * 2016-11-14 2018-05-17 Dompe' Farmaceutici S.P.A. Préparation de composition de granules de canneberge enrobés ayant une teneur en pacs stable
EP3320897A1 (fr) * 2016-11-14 2018-05-16 Dompè Primary S.r.l Préparation de granules de cranberry enrobés à teneur stable en proanthocyanidines
RU2766084C2 (ru) * 2016-11-14 2022-02-07 Домпе Фармачеутичи С.П.А. Получение композиции клюквенных гранул с устойчивым содержанием проантоцианидинов
CN110799198A (zh) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 用于稳定阴道液的酸度和氧化还原状态的基于合适的生化组合物的泌尿生殖器医疗设备制剂
WO2018100533A1 (fr) 2016-11-30 2018-06-07 Probioswiss Ag Formulation de dispositif médical urogénital à base de compositions biochimiques appropriées pour la stabilisation de l'acidité et de l'état redox des sécrétions vaginales
US11235060B2 (en) 2016-11-30 2022-02-01 Probioswiss Ag Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid
CN113662175A (zh) * 2021-08-16 2021-11-19 广州市沐家健康产业有限公司 一种植物基酵素液排毒养颜组合物及其制备方法
CN113662175B (zh) * 2021-08-16 2022-05-03 广州市沐家健康产业有限公司 一种植物基酵素液排毒养颜组合物及其制备方法

Also Published As

Publication number Publication date
JPH11504049A (ja) 1999-04-06
AU1854297A (en) 1997-09-02
CA2246371A1 (fr) 1997-08-21
CN1211189A (zh) 1999-03-17
EP0881905A1 (fr) 1998-12-09

Similar Documents

Publication Publication Date Title
WO1997029763A1 (fr) Compositions pour le traitement de troubles urogenitaux et intestinaux contenant une substance derivee d'especes de plantes de la famille des ericaceae et un facteur de croissance de bacteries d'acide lactique
WO1997029762A1 (fr) Compositions destinees au traitement de troubles urogenitaux et intestinaux
DE60023919T2 (de) Verbesserte topische zusammensetzungen mit extrazellulären produkten von probiotischen bakterien und verwendungen davon
JP4678896B2 (ja) 微生物感染を予防または制御するための共生Ｂａｃｉｌｌｕｓ芽胞の局所的使用
JP6509822B2 (ja) 細菌性腟症の予防的および／または治療的処置に使用するための乳酸菌含有組成物
EP2087094B1 (fr) Lactobacillus fermentum ess-1, dsm17851 et son utilisation pour le traitement et/ou la prévention de la candidose et des infections des voies urinaires
US7507402B1 (en) Topical use of probiotic Bacillus spores to prevent or control microbial infections
CN102065837A (zh) 枸杞提取物用于保持和/或恢复皮肤张力和/或紧致的用途
EP2158916A1 (fr) Unité d'administration contenant des bactéries produisant de l'acide lactique
MX2012004509A (es) Composicion externa para la piel que comprende una sal y azucar como ingredientes activos para prevenir y tratar la vaginosis y uso de la misma.
KR101838404B1 (ko) 올리고키토산을 유효성분으로 함유하는 여드름 예방 또는 치료용 조성물
KR102519415B1 (ko) 질염 예방 또는 치료용 조성물
AU783905B2 (en) Use of emu oil carrier for antifungal, antibacterial, and antiviral medications
CN117679352A (zh) 一种生物酶基组合物、含有该组合物的降糖牙膏及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192256.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 331260

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2246371

Country of ref document: CA

Ref document number: 2246371

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 529374

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997904185

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997904185

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997904185

Country of ref document: EP